Elitek (Rasburicase) Immuno-Monitoring Study

Tumor Lysis Syndrome Clinical Trial

Official title:
A Multicenter Registry Study of Anti-rasburicase Antibodies in Patients Retreated With Rasburicase (SR29142) in the Context of Relapsing Leukemia/Lymphoma Who Experienced Subsequent Hypersensitivity Reaction(s) or Loss of Uricolytic Activity: An Immuno-Monitoring Observational Study

Status Terminated

Clinical Trial Summary

Primary Objective:

To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Tumor Lysis Syndrome

Clinical Trial Details

NCT number	NCT01097369
Study type	Observational
Source	Sanofi
Contact
Status	Terminated
Phase	N/A
Start date	February 2010
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01724528` - Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies	Phase 3
Completed	`NCT00186940` - Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients	N/A
Completed	`NCT00230217` - Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy	Phase 4
Completed	`NCT00360438` - Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS	Phase 1/Phase 2
Completed	`NCT00651911` - Fasturtec TLS Treatment / Prophylysis	Phase 4
Completed	`NCT00628628` - Rasburicase in Patients at Risk for Tumor Lysis Syndrome	Phase 2
Terminated	`NCT03605212` - Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults	Phase 1/Phase 2
Active, not recruiting	`NCT04745910` - Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome	Phase 4
Completed	`NCT00230178` - Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome	Phase 3